Display options
Cite
Zheng P, Liang C, Ren L, et al. Additional Biomarkers beyond RAS That Impact the Efficacy of Cetuximab plus Chemotherapy in mCRC: A Retrospective Biomarker Analysis. J Oncol. 2018;2018:5072987doi: 10.1155/2018/5072987.
Zheng, P., Liang, C., Ren, L., Zhu, D., Feng, Q., Chang, W., He, G., Ye, L., Chen, J., Lin, Q., Yi, T., Ji, M., Niu, Z., Jian, M., Wei, Y., & Xu, J. (2018). Additional Biomarkers beyond RAS That Impact the Efficacy of Cetuximab plus Chemotherapy in mCRC: A Retrospective Biomarker Analysis. Journal of oncology, 20185072987. https://doi.org/10.1155/2018/5072987
Zheng, Peng, et al. "Additional Biomarkers beyond RAS That Impact the Efficacy of Cetuximab plus Chemotherapy in mCRC: A Retrospective Biomarker Analysis." Journal of oncology vol. 2018 (2018): 5072987. doi: https://doi.org/10.1155/2018/5072987
Zheng P, Liang C, Ren L, Zhu D, Feng Q, Chang W, He G, Ye L, Chen J, Lin Q, Yi T, Ji M, Niu Z, Jian M, Wei Y, Xu J. Additional Biomarkers beyond RAS That Impact the Efficacy of Cetuximab plus Chemotherapy in mCRC: A Retrospective Biomarker Analysis. J Oncol. 2018 Sep 16;2018:5072987. doi: 10.1155/2018/5072987. eCollection 2018. PMID: 30305811; PMCID: PMC6165607.
Copy Download .nbib Format: NLM
Share it on

J Oncol. 2018 Sep 16;2018:5072987. doi: 10.1155/2018/5072987. eCollection 2018.

Additional Biomarkers beyond RAS That Impact the Efficacy of Cetuximab plus Chemotherapy in mCRC: A Retrospective Biomarker Analysis.

Journal of oncology

Peng Zheng, Chunmin Liang, Li Ren, Dexiang Zhu, Qingyang Feng, Wenju Chang, Guodong He, Lechi Ye, Jingwen Chen, Qi Lin, Tuo Yi, Meiling Ji, Zhengchuan Niu, Mi Jian, Ye Wei, Jianmin Xu

Affiliations

  1. Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
  2. Department of Anatomy, Histology & Embryology, Shanghai Medical College, Fudan University, Shanghai, China.
  3. Department of Oncological Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.

PMID: 30305811 PMCID: PMC6165607 DOI: 10.1155/2018/5072987

Abstract

PURPOSE: We aimed to identify new predictive biomarkers for cetuximab in first-line treatment for patients with RAS wild-type metastatic colorectal cancer (mCRC).

METHODS: The study included patients with KRAS wild-type unresectable liver-limited mCRC treated with chemotherapy with or without cetuximab. Next-generation sequencing was done for single nucleotide polymorphism according to custom panel. Potential predictive biomarkers were identified and integrated into a predictive model within a training cohort. The model was validated in a validation cohort.

RESULTS: Thirty-one of 247(12.6%) patients harbored RAS mutations. In training cohort (N=93), six potential predictive genes, namely, ATP6V1B1, CUL9, ERBB2, LY6G6D, PTCH1, and RBMXL3, were identified. According to predictive model, patients were divided into responsive group (n=66) or refractory group (n=27). In responsive group, efficacy outcomes were significantly improved by addition of cetuximab to chemotherapy. In refractory group, no benefit was observed. Interaction test was significant across all endpoints. In validation cohort (N=123), similar results were also observed.

CONCLUSIONS: In the first-line treatment of mCRC, the predictive model integrating six new predictive mutations divided patients well, indicating a promising approach to further refine patient selection for cetuximab on the basis of RAS mutations.

References

  1. Am Soc Clin Oncol Educ Book. 2015;:e149-56 - PubMed
  2. Clin Cancer Res. 2015 Oct 15;21(20):4686-97 - PubMed
  3. Gut. 2015 Apr;64(4):636-45 - PubMed
  4. J Clin Oncol. 2015 Mar 1;33(7):692-700 - PubMed
  5. Clin Cancer Res. 2015 Oct 1;21(19):4461-72 - PubMed
  6. J Clin Oncol. 2013 Oct 20;31(30):3764-75 - PubMed
  7. J Clin Oncol. 2011 May 20;29(15):2011-9 - PubMed
  8. Nat Rev Mol Cell Biol. 2005 Jan;6(1):9-20 - PubMed
  9. Acta Oncol. 2013 Jun;52(5):956-62 - PubMed
  10. Lancet Oncol. 2014 Sep;15(10):1065-75 - PubMed
  11. Clin Colorectal Cancer. 2012 Jun;11(2):143-50 - PubMed
  12. J Clin Oncol. 2013 Jun 1;31(16):1931-8 - PubMed
  13. Biochem J. 2003 Oct 1;375(Pt 1):207-13 - PubMed
  14. Cell. 2012 May 25;149(5):1098-111 - PubMed
  15. Lancet Oncol. 2010 Aug;11(8):753-62 - PubMed
  16. Ann Oncol. 2017 Aug 1;28(8):1713-1729 - PubMed
  17. Eur J Cancer. 2015 Jul;51(10):1243-52 - PubMed
  18. Cancer Discov. 2013 Jun;3(6):658-73 - PubMed
  19. Cancer Discov. 2011 Nov;1(6):508-23 - PubMed
  20. Nature. 2015 Oct 8;526(7572):263-7 - PubMed
  21. Cancer Discov. 2014 Nov;4(11):1269-80 - PubMed
  22. Clin Chem Lab Med. 2014 May;52(5):707-14 - PubMed
  23. Nat Commun. 2017 Mar 10;8:14688 - PubMed

Publication Types